Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity

Todd, Derrick J.; Kay, Jonathan

doi:10.1007/s11926-008-0033-6

Cited by 32 publications

(26 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The skin changes are often accompanied by other symptoms such as pain, swelling, nausea, vomiting, muscle weakness, and joint stiffness. It also affects other organs and visceral fibrosis of the heart, lungs, and other organs can occur [285]. The first case of NSF was reported in 2000 [286].…”

Section: Nephrogenic Systemic Fibrosis (Nsf)mentioning

confidence: 99%

“…While the diagnosis of scleromyxedema is confirmed by a positive 7S-IgG paraprotein test, this was characteristically negative in the new disease [286]. It remains challenging to distinguish NSF from other fibrosing disorders and clinical, histopathological, and laboratory test results must be considered to reach a specific diagnosis [285,290]. In 2006, an association of NSF with Gd 3+ -based MRI contrast agents was suggested and subsequently several retrospective analyses of NSF cases revealed that essentially all NSF patients received a Gd 3+ -based contrast agent prior to disease onset [291][292][293][294][295].…”

Section: Nephrogenic Systemic Fibrosis (Nsf)mentioning

confidence: 99%

“…However, at present, there is no model that satisfactorily predicts NSF occurrence. Also, there is no effective treatment of NSF currently available [285,315]. Several therapies (photopheresis, plasmapheresis, sodium thiosulfate, and imatinib mesylate) have been attempted but with inconsistent results.…”

Section: Nephrogenic Systemic Fibrosis (Nsf)mentioning

confidence: 99%

See 2 more Smart Citations

Stability and Toxicity of Contrast Agents

Brücher

Tircsó

Baranyai

et al. 2013

The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging

View full text Add to dashboard Cite

Magnetic Resonance Imaging (MRI) derives directly from the phenomenon of Nuclear Magnetic Resonance (NMR [1][2][3][4]), which is widely used by chemists to determine molecular structure. The word "nuclear" was dropped in the switch to imaging to avoid alarming patients as NMR has nothing to do with radioactivity. This book is intended mainly for chemists, who are generally familiar with the NMR spectra. After a brief overview of the technique explaining the notion of relaxation time and saturation transfer used in MRI, we will describe localization techniques, which are less well-known in chemistry. The purpose of this short chapter is not to provide a complete theory of MRI [5][6][7][8], but to understand the rest of the book concerning the action of contrast agents. We will not go into the theoretical background of the phenomena, and while it is important to have some understanding of quantum mechanics, it is not our purpose to develop this aspect. This is a "nuts and bolts" description of MRI. Whenever possible, we refer to chemists' knowledge of NMR (for example, "2D NMR"). Theoretical basis of NMR Short description of NMRIn most cases, MRI focuses on one type of atomic nucleus, that of hydrogen in H 2 O. We will therefore only use this nucleus, termed the " 1 H proton."The physical phenomenon of NMR lies at the boundary between "conventional" and "quantum" treatment due to the small transition energies involved. Traditionally, the 1 H proton can be considered as a charged

show abstract

Section: Nephrogenic Systemic Fibrosis (Nsf)mentioning

confidence: 99%

Section: Nephrogenic Systemic Fibrosis (Nsf)mentioning

confidence: 99%

See 1 more Smart Citation

Stability and Toxicity of Contrast Agents

Brücher

Tircsó

Baranyai

et al. 2013

The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…These rheumatic disorders have been well described and carefully studied for many years ( Table 1 ). Gadoliniumassociated systemic fi brosis (nephrogenic systemic fi brosis) is a relatively new but ominous disease affecting patients with chronic kidney disease (CKD) and has been described recently in this journal [ 3 ]. Because the incidence of β 2 -microglobulin amyloidosis has decreased markedly over the past decade, we will not discuss this disorder that previously affected many patients with stage 5 CKD (glomerular fi ltration rate [GFR] < 15 mL/min or receiving dialysis).…”

Section: Introductionmentioning

confidence: 99%

Non-crystalline and crystalline rheumatic disorders in chronic kidney disease

Sarraf¹,

Kay²

2008

Curr Rheumatol Rep

Self Cite

View full text Add to dashboard Cite

Rheumatic syndromes are cause for morbidity in patients with end-stage renal disease. Recent advances in understanding the role of tissue remodeling have provided insight into the pathogenic mechanisms responsible for some of these manifestations. Here, we survey recent and clinically relevant advances in translational research that impact our understanding of rheumatic syndromes seen in patients with significant renal disease. The management of acute and chronic crystalline arthropathies in chronic kidney disease and hemodialysis patients is discussed.

show abstract

“…Its original name, nephrogenic fibrosing dermopathy, was changed to NSF once it became evident that fibrosis of other organs, including the heart, lungs, liver, lymph nodes, central nervous system, and muscle, also occurs (2,3). Since 2000, more than 200 cases have been reported worldwide, both in publications and to regulatory authorities (4).…”

mentioning

confidence: 99%

Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients

Abujudeh

Rolls

Kaewlai

et al. 2009

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

Stage 3-5 chronic kidney disease (CKD) undergoing gadobenate dimeglumine (GBD)-enhanced magnetic resonance (MR) examinations were included in the retrospective investigation. The electronic medical records were reviewed to assess the prevalence of nephrogenic systemic fibrosis (NSF) in renally impaired patients underwent GBDenhanced MR examinations. In all, 250 patients (98 men, mean age 72.6 years) were included: 97% of the patients had Stage 3 CKD (estimated GFR 30-59 mL/min/ 1.73 m 2 ); 37% had been exclusively exposed to GBD. The remaining were exposed to GBD and other gadoliniumbased contrast agents (GBCAs). The mean dose of GBD was 22 mL (standard deviation [SD], 11.2). Including exposure to other GBCAs, the mean cumulative dose of gadolinium was 61 mL (SD, 62.3). A total of 206 patients (82%) had skin examinations following the last GBD administration (mean duration, 108 days). No evidence of suspected or diagnosed NSF was found. In conclusion, on the basis of a retrospective chart review there was no skin evidence of NSF in predominantly Stage 3 CKD patients who were exposed to GBD at an average followup of 108 days, either solely or in combination with other GBCAs.

show abstract

Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity

Cited by 32 publications

References 80 publications

Stability and Toxicity of Contrast Agents

Stability and Toxicity of Contrast Agents

Non-crystalline and crystalline rheumatic disorders in chronic kidney disease

Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients

Contact Info

Product

Resources

About